ReviewBiomarkers in medicine2010
Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis.
Review in Biomarkers in medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.
- Pooled it
- Mendelian randomization of serum urate and parkinson disease progression.Annals of neurology · 2014Trial
- The power of five - inositol polyphosphate 5-phosphatase gene mutations at the intersection of development and disease.FEBS letters · 2026Review
- Classification of Parkinson's disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome.NPJ Parkinson's disease · 2025Article
- The impact of uric acid levels in the pathophysiology and its contribution to the prediction of diagnosis in restless legs syndrome.Sleep and biological rhythms · 2025Article
- Pre-clinical Aspects and Contemporary Treatments of Parkinson's Disease.CNS & neurological disorders drug targets · 2024Review
- Thermodynamic Signatures of Blood Plasma Proteome in Neurodegenerative Pathologies.International journal of molecular sciences · 2023Article
- Shared Molecular Targets in Parkinson's Disease and Arterial Hypertension: A Systematic Review.Biomedicines · 2022Review
- Article
- Serum fractalkine and 3-nitrotyrosine levels correlate with disease severity in Parkinson's disease: a pilot study.Metabolic brain disease · 2022Article
- Hyperuricemia and the small intestine: Transport mechanisms and co-morbidities.Biotechnology notes (Amsterdam, Netherlands) · 2022Review
- Parkinson's Disease and the Gut Microbiome in Rural California.Journal of Parkinson's disease · 2022Article
- Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis.Molecular neurobiology · 2021Review
- Current advances in metabolomic studies on non-motor psychiatric manifestations of Parkinson's disease (Review).Experimental and therapeutic medicine · 2021Review
- Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease.Nature communications · 2021Article
- Metabotropic glutamate receptor 5 inhibits α-synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson's disease.Journal of neuroinflammation · 2021Article
- Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough.Frontiers in aging neuroscience · 2021Review
- Inosine as a Tool to Understand and Treat Central Nervous System Disorders: A Neglected Actor?Frontiers in neuroscience · 2021Review
- Elevated salivary uric acid levels among adolescents with eating disorders.Eating and weight disorders : EWD · 2020Article
- The Relationship Between Serum Uric Acid Levels and Clinical Features in Essential Tremor.Noro psikiyatri arsivi · 2020Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
A growing number of studies have correlated higher urate levels with a lower risk of developing Parkinson's disease (PD) and with a favorable rate of disease progression, indicating that urate could be an important biomarker of the pathophysiology underlying PD. Dietary and genetic determinants of urate have also been linked to a reduced risk or delayed onset of PD. Based on the known antioxidant and metal complexing properties of urate, together with evidence for oxidative stress as a contributor to neurodegeneration in PD, urate may serve as an endogenous neuroprotectant that helps reduce the risk and rate of the disease. In this article we review the convergent biological, epidemiological and clinical data that identify urate as a promising biomarker of the risk, diagnosis and prognosis of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.